Clinical Immuno-Monitoring

Monitoring the quality and quantity of cellular immune responses in clinical immunotherapy trials aids in evaluating the efficacy of treatment. The nature of the cellular immune response generated could impact the further development of immunotherapeutics, also known as immunoguiding. High-parameter flow cytometry offers a tool addressing multiple markers on samples of different origin (e.g. blood, organs, tumor) containing a heterogeneous composition of cell types with a statistical robustness. This technology thereby creates immunological signatures for a variety of decisive descriptors, such as early failure, prognostic marker, predictive marker and/or substitute for clinical endpoint testing.

TRON’s immunomonitoring team operates a suite of flow cytometers with the capacity to capture tailored, multiple marker sets addressing different types of immune cells. This activity includes phenotyping, activation status and cytokine production profile upon stimulation of cells. Our scientists have set up multiple marker panels for different questions and provide consulting, analysis and data interpretation to internal colleagues and collaborations partners.

All the methods are established as standard operating procedures (SOPs) as a component of our internal quality assurance system.

Our Platforms

  • LSR Fortessa SORP (5 laser, 18+2 parameter)
  • FACSCanto II (3 lasers, 8+2 parameters, high throughput sampler)
  • FACSAria III Cell Sorter (3 lasers, 11+2 parameters)

Our Customized Flow Panels Identify:

  • Antigen-specific T cells and their phenotype (multimer technology), activation markers
  • Regulatory T Cells, gd T cells and activation markers
  • Leukocyte subsets and activation markers
  • Stem-like T cells
  • NK cells and MDSCs
  • Intracellular cytokine production

Key Contributions and Publications

Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Kemmer-Brück A, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö. (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547(7662):222-226.  DOI; PUBMED

Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U. (2016) Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 534(7607):396-40. DOI; PUBMED

Kreiter S, Diken M, Selmi A, Petschenka J, Türeci Ö, Sahin U. (2-16) FLT3 Ligand as a Molecular Adjuvant for Naked RNA Vaccines. Methods Mol Biol. 1428:163-75 DOI; PUBMED

Simon P, Omokoko TA, Breitkreuz A, Hebich L, Kreiter S, Attig S, Konur A, Britten CM, Paret C, Dhaene K, Tureci Ö, Sahin U. (2014) Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes. Cancer Immunol. Res. 2(12):1230–1244.  DOI; PUBMED

Diken M, Kreiter S, Vascotto F, Selmi A, Attig S, Diekmann J, Huber C, Türeci Ö, Sahin U. (2013) mTOR inhibition improves antitumor effects of vaccination with antigen-encoding RNA. Cancer Immunol. Res. 1:386-392.  DOI; PUBMED

Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters MJP, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM. (2012) Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. Cancer Immunol. Immunother. 62(4):615-27. DOI: PUBMED

More Technologies and Platforms